Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

6.3K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

2.9K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.9K
Electron Transport Chain: Complex I and II01:46

Electron Transport Chain: Complex I and II

19.5K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
19.5K
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

4.3K
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
4.3K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.9K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Metastatic Colorectal Cancer Beyond Third-Line Treatment: Systematic Review and Meta-Analysis of Later-Line Therapies.

Journal of clinical medicine·2026
Same author

Breast Cancer Risk in over 1.3 Million Women on Antipsychotic Therapy: Life-Saving Drugs or Hidden Trigger for Breast Cancer?

Medical sciences (Basel, Switzerland)·2026
Same author

Antibiotic Resistance Pattern and Surgical Outcome in Complicated Intra-Abdominal Infections Due to Colorectal Perforation.

Antibiotics (Basel, Switzerland)·2026
Same author

Cost-effectiveness of ivosidenib in patients with previously treated isocitrate dehydrogenase 1 (IDH1)-mutant cholangiocarcinoma: An Italian perspective.

Hepatobiliary & pancreatic diseases international : HBPD INT·2026
Same author

The Current Role of Antiangiogenics in Colorectal Cancer.

International journal of molecular sciences·2025
Same author

Cost-effectiveness of liposomal irinotecan (nal-IRI) combined with 5-fluorouracil and leucovorin in second or subsequent lines for metastatic pancreatic cancer in Italy. It can be done.

Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]·2025

Related Experiment Video

Updated: Mar 27, 2026

Amide Coupling Reaction for the Synthesis of Bispyridine-based Ligands and Their Complexation to Platinum as Dinuclear Anticancer Agents
07:20

Amide Coupling Reaction for the Synthesis of Bispyridine-based Ligands and Their Complexation to Platinum as Dinuclear Anticancer Agents

Published on: May 28, 2014

14.6K

[Platinum antitumor complexes].

Andrea Bonetti, Jacopo Giuliani, Franco Muggia

    Recenti Progressi in Medicina
    |January 19, 2016
    PubMed
    Summary
    This summary is machine-generated.

    Cisplatin, discovered 50 years ago, revolutionized testicular cancer treatment, transforming it from fatal to curable. Ongoing research focuses on platinum-based drugs, reducing toxicity, and overcoming resistance.

    More Related Videos

    Anticancer Metal Complexes: Synthesis and Cytotoxicity Evaluation by the MTT Assay
    11:14

    Anticancer Metal Complexes: Synthesis and Cytotoxicity Evaluation by the MTT Assay

    Published on: November 10, 2013

    59.1K
    A Tripeptide-Stabilized Nanoemulsion of Oleic Acid
    10:42

    A Tripeptide-Stabilized Nanoemulsion of Oleic Acid

    Published on: February 27, 2019

    10.0K

    Related Experiment Videos

    Last Updated: Mar 27, 2026

    Amide Coupling Reaction for the Synthesis of Bispyridine-based Ligands and Their Complexation to Platinum as Dinuclear Anticancer Agents
    07:20

    Amide Coupling Reaction for the Synthesis of Bispyridine-based Ligands and Their Complexation to Platinum as Dinuclear Anticancer Agents

    Published on: May 28, 2014

    14.6K
    Anticancer Metal Complexes: Synthesis and Cytotoxicity Evaluation by the MTT Assay
    11:14

    Anticancer Metal Complexes: Synthesis and Cytotoxicity Evaluation by the MTT Assay

    Published on: November 10, 2013

    59.1K
    A Tripeptide-Stabilized Nanoemulsion of Oleic Acid
    10:42

    A Tripeptide-Stabilized Nanoemulsion of Oleic Acid

    Published on: February 27, 2019

    10.0K

    Area of Science:

    • Oncology
    • Cancer Therapeutics
    • Medicinal Chemistry

    Background:

    • Malignant germ-cell testicular tumors were once highly fatal.
    • The discovery of cisplatin by Barnett Rosenberg in 1965 marked a turning point in oncology.
    • This year marks the 50th anniversary of cisplatin's discovery.

    Purpose of the Study:

    • To commemorate the 50th anniversary of cisplatin's discovery.
    • To review key aspects of platinum-based cancer therapeutics.
    • To highlight advancements and ongoing challenges in the field.

    Main Methods:

    • Review of Barnett Rosenberg's legacy and contributions.
    • Examination of the development of cisplatin analogs (e.g., carboplatin, oxaliplatin).
    • Discussion of clinical research on mitigating cisplatin toxicities and overcoming platinum resistance.

    Main Results:

    • Cisplatin has transformed testicular cancer from a highly fatal disease to one with a near-uniform cure rate.
    • Development of less toxic analogs like carboplatin has improved patient outcomes.
    • Oxaliplatin has expanded the therapeutic applications of platinum compounds.

    Conclusions:

    • The discovery of cisplatin represents a landmark achievement in cancer therapy.
    • Continued research into platinum compounds, their toxicities, and resistance mechanisms is crucial.
    • Advancements in cancer biology are integral to evolving therapeutic strategies.